This invention provides compounds defined by Formula I
##STR1##
or a pharmaceutically acceptable salt thereof,
wherein R1, Q, Y2, Y3, Y4, U5,
U6, U8, and R2 are as defined in the specification.
The invention also provides pharmaceutical compositions comprising a compound of
Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification,
together with a pharmaceutically acceptable carrier, diluent, or excipient. The
invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising
administering to the animal a compound of Formula I, or a pharmaceutically acceptable
salt thereof. The invention also provides methods of treating a disease mediated
by an MMP-13 enzyme in a patient, comprising administering to the patient a compound
of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in
a pharmaceutical composition. The invention also provides methods of treating diseases
such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis
other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory
bowel disease, heart failure, age-related macular degeneration, chronic obstructive
pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and
osteoporosis in a patient, comprising administering to the patient a compound of
Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a
pharmaceutical composition. The invention also provides combinations, comprising
a compound of Formula I, or a pharmaceutically acceptable salt thereof, together
with another pharmaceutically active component as described in the specification.
